This study is a long-term extension for people who have already participated in two previous trials, called **APPROACH** and **EMBRACE**. It focuses on the safety and long-term effects of a medication named **CYB003** for treating Major Depressive Disorder (**MDD**). To join, you must have completed both doses in the prior trials and continued with the same antidepressant medication. If you can have children, you need to use reliable birth control during and after the study.

Key Points:

• Participants must have finished the previous trials and received both doses.
• Females must pass a pregnancy test at the study start and before dosing.
• The study involves keeping to birth control rules for 12 weeks post-final dose.

People with new symptoms of schizophrenia, significant suicide risk, or heart issues are not eligible. Additionally, those with drug or alcohol issues, or who are sensitive to CYB003, cannot participate. Participants must also agree to be recorded during sessions for research purposes.